Welcome to our dedicated page for Lineage Cell The SEC filings (Ticker: LCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lineage Cell Therapeutics, Inc. filings document the disclosures of a clinical-stage biotechnology company developing allogeneic cell therapies and cell transplant product candidates. The company’s reports and current-event filings cover financial results, business updates, pipeline developments, research collaborations, clinical-program milestones, and manufacturing progress involving programs such as OpRegen, OPC1, and ReSonance.
Regulatory filings also describe Lineage’s capital structure and financing activity, including common share offerings under shelf registration and at-the-market arrangements. Proxy materials cover board matters, executive compensation, equity awards, shareholder voting items, and governance disclosures, while 8-K filings record material events tied to collaborations, grant-related developments, operating results, and other corporate updates.
On August 12, 2025, Lineage Cell Therapeutics furnished a press release announcing its financial results for the quarter ended June 30, 2025, which is provided as Exhibit 99.1. The Form 8-K states the information is being furnished, not filed, and therefore is not incorporated by reference into other filings. The filing also includes an Inline XBRL cover page as Exhibit 104. The report is signed by George A. Samuel III, General Counsel and Corporate Secretary.
Lineage Cell Therapeutics announced promising 36-month results from their Phase 1/2a clinical study of RG6501 (OpRegen®) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Key findings include:
- Visual Acuity Improvements: Cohort 4 patients (less advanced GA) showed sustained improvement through 36 months, with mean BCVA gains of +6.2 letters overall and +9.0 letters in patients with extensive OpRegen coverage
- Structural Improvements: Sustained retinal structural improvements observed through OCT analysis, with treated eyes maintaining RPEDC area (+1.9 mm²) while untreated eyes declined (-3.8 mm²)
- Current Development: A Phase 2a "GAlette" study (NCT05626114) is actively enrolling patients, testing new proprietary surgical devices for OpRegen delivery
The therapy is being developed through a worldwide collaboration between Lineage, Roche, and Genentech. Results suggest OpRegen cell therapy may provide durable support to remaining retinal cells within atrophic areas for at least 36 months after a single administration.